Arena Capital Advisors’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Arena Capital Advisors’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-225,899	Closed	-$2.26M	–	435
2021 Q2	$2.26M	Sell	225,899 -74,101	-25%	-$742K	0.19%	163
2021 Q1	$3.02M	Buy	+300,000	New	+$3M	0.3%	109

Other funds holding EBACU

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return

Arena Capital Advisors's EBACU Position: Q3 2021 in Review

Arena Capital Advisors sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2021, closing a stake of 225,899 shares — an estimated $2.26M sold.

Arena Capital Advisors first reported a position in EBACU in Q1 2021 and held it in 2 quarters. The position peaked at $3.02M in Q1 2021. 30 funds tracked by Wall St. Rank hold EBACU as of Q3 2021.

Arena Capital Advisors reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2021 after selling out during the quarter.
Arena Capital Advisors sold 225,899 European Biotech Acquisition Corp. Units shares in Q3 2021, an estimated $2.26M.
Arena Capital Advisors first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 2 quarters.
Arena Capital Advisors's European Biotech Acquisition Corp. Units position peaked at $3.02M in Q1 2021.
30 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2021.

Based on Arena Capital Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.